logo-loader

Humanigen teams up with Kite to treat a type of lymphoma cancer

Published: 19:13 10 Jun 2019 BST

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based biotech has forged a clinical collaboration with Gilead Sciences Inc's (NASDAQ:GILD) subsidiary Kite, to study its therapy lenzilumab, with Kite's drug called Yescarta in patients suffering with certain forms of lymphoma cancer.

Durrant says he expects this Phase 1/2 study to begin by the end of 2019.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 57 minutes ago